Drug Trial Radar · NCT02566993
Clinical Trial of Lurbinectedin (PM01183)/Doxorubicin Versus CAV or Topotecan as Treatment in Patients With Small-Cell Lung Cancer
Last checked: Nov 20, 2026Latest source record: Oct 28, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
613
Actual
Start
Aug 30, 2016
Primary completion
Feb 24, 2020
Study completion Feb 24, 2020
Sponsor
- Lead sponsor
- PharmaMarIndustry
- Sponsor type
- Industry
- First posted
- Oct 2, 2015
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Phase III randomized clinical trial of lurbinectedin (PM01183)/doxorubicin (DOX) versus cyclophosphamide (CTX), doxorubicin (DOX) and vincristine (VCR) (CAV) or topotecan as treatment in patients with small-cell lung cancer (SCLC) who failed one prior platinum-containing line.
Conditions
- Small-cell Lung Cancer
Interventions
Lurbinectedin (PM01183)Drug
Doxorubicin (DOX)Drug
Cyclophosphamide (CTX)Drug
Vincristine (VCR)Drug
TopotecanDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Survival (OS)Time frame: Every three months up to death or study termination, a period of approximately 3.5 years
Locations
160 sites in 20 countries. Site status is shown where the registry gives one.
Alabama Oncology
Birmingham, Alabama
Ironwood Physicians P.C. dba Ironwood Cancer & Research Centers
Chandler, Arizona
St Jude Hospital Yorba Linda dba St Joseph Heritage Healthcare
Fullerton, California
Loma Linda University Medica! Center
Loma Linda, California
Innovative Clinical Research Institute (ICRI)
Whittier, California
Boca Raton Regional Hospital Lynn Cancer Institute
Boca Raton, Florida
Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center
Fort Lauderdale, Florida
H. Lee Moffitt Cancer Center & Research Institute
Tampa, Florida
Joliet Oncology-Hematology Associates, Ltd.
Joliet, Illinois
Healthcare Research Network III, LLC
Tinley Park, Illinois
Carle Cancer Center
Urbana, Illinois
Norton Cancer Institute
Louisville, Kentucky
Montgomery Cancer Center
Mount Sterling, Kentucky
East Jefferson Hematology-Oncology Metairie Physicians Services, Inc
Metairie, Louisiana
Anne Arundel Medical Center Oncology and Hematology
Annapolis, Maryland
Massachusetts General Hospital
Boston, Massachusetts
QUEST Research Institute
Royal Oak, Michigan
Comprehensive Cancer Centers of Nevada
Las Vegas, Nevada
Dartmouth-Hitchcock Medical Center/Mary Hitchcock Memorial Hospital
Lebanon, New Hampshire
Summit Medical Group, P.A.
Florham Park, New Jersey
FirstHealth Outpatient Cancer Center
Pinehurst, North Carolina
Gabrail Cancer Center Research
Canton, Ohio
Oklahoma Cancer Specialists and Research Institute, LLC
Tulsa, Oklahoma
Associates in Hematology and Oncology, P.C.
Upland, Pennsylvania
The Center for Cancer and Blood Disorders
Fort Worth, Texas
Tyler Hematology-Oncology PA
Tyler, Texas
Medical Oncology Associates PS (dba Summit Cancer Centers)
Spokane, Washington
MultiCare Institute for Research & Innovation
Tacoma, Washington
Froedtert Hospital & the Medical College of Wisconsin
Milwaukee, Wisconsin
Instituto Oncológico de Córdoba (IONC)
Córdoba, Argentina
CORI - Centro Oncológico Riojano Integral
La Rioja, Argentina
ISIS Centro Especializado de Luce S.A.
Santa Fe, Argentina
Instituto Médico Especializado Alexander Fleming
C.a.b.a., Buenos Aires, Argentina
Centro para la Atención Integral del Paciente Oncológico (CAIPO)
San Miguel de Tucumán, Tucumán Province, Argentina
Universitätsklinik für Innere Medizin III der PMU
Salzburg, Austria
Medizinische Universität Wien / AKH Wien, Universitätsklinik für Innere Medizin I, Abteilung für klinische Onkologie
Vienna, Austria
AZ Maria Middelares
Ghent, Belgium
Clinique André Renard
Herstal, Belgium
CHR de la citadelle
Liège, Belgium
CHU de Liege - Sart Tilman
Liège, Belgium
Showing 40 of 160 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.